Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

Medical Oncology, published by Humana Press Inc, stands as a significant contributor to the field of oncology, with its long-standing commitment to disseminating research and clinical findings relevant to the treatment and management of cancer. Established in 1994 and continuing through 2024, this journal publishes insightful articles that reflect the latest advancements in cancer research, hematology, and related medical fields. With an evolving impact factor and remarkable categorizations, including Q3 in Cancer Research and Q2 in both Hematology and Oncology, Medical Oncology serves as a pivotal resource for healthcare providers, researchers, and students dedicated to improving cancer outcomes. Although it does not offer open access, the journal is widely recognized for its rigorous peer-review process and high-quality publications, making it an essential platform for sharing innovative research and critical reviews in oncology.

NEOPLASMA is a prominent journal published by AEPRESS SRO, dedicated to the multifaceted field of oncology and cancer research. Since its inception in 1957, this esteemed publication has served as a vital platform for advancing the understanding of neoplastic diseases, disseminating high-quality research findings that contribute to clinical and laboratory advancements. Operating under a robust framework of peer review, NEOPLASMA holds significant credibility, as evidenced by its Q2 ranking in the Medicine (miscellaneous) category and Q3 rankings in both Cancer Research and Oncology for 2023. Furthermore, with an ISSN of 0028-2685 and E-ISSN 1338-4317, the journal fosters accessibility to valuable scientific content despite the absence of open access options. Positioned in Bratislava, Slovakia, NEOPLASMA continues to attract a global readership, making substantial contributions to the fields of biochemistry, genetics, and molecular biology as highlighted by its Scopus rankings. This journal is essential reading for researchers, professionals, and students looking to stay abreast of the latest developments in cancer research and treatment strategies.

MOLECULAR CARCINOGENESIS is a prestigious academic journal published by Wiley, dedicated to advancing the understanding of the molecular basis of cancer. Established in 1988, this journal serves as a vital resource for researchers and professionals in the fields of cancer research and molecular biology. With an impressive impact factor reflecting its significance in the Q2 category for both Cancer Research and Molecular Biology, it stands out for its high-quality, peer-reviewed articles that explore innovative research, novel findings, and emerging trends in carcinogenesis. Although the journal currently does not offer open access options, it remains accessible to the academic community through numerous institutional subscriptions. Positioned in the United States and contributing to the global discourse on cancer research, MOLECULAR CARCINOGENESIS is an essential publication for anyone engaged in the study of cancer at the molecular level.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Cancer Reports, published by WILEY, is an esteemed open-access journal dedicated to the field of oncology and cancer research. With a focus on disseminating impactful research findings since its transition to fully open access in 2021, Cancer Reports aims to facilitate knowledge sharing among researchers, clinicians, and healthcare professionals globally. The journal is positioned within the Q3 quartile for both Cancer Research and Oncology categories as of 2023, reflecting its commitment to quality and relevance in a competitive publishing landscape. With an ISSN of N/A and an E-ISSN of 2573-8348, the journal showcases studies across diverse aspects of cancer biology, treatment modalities, and patient care strategies. Located in the United Kingdom at 111 River St, Hoboken 07030-5774, NJ, Cancer Reports strives to contribute to the advancement of cancer research and improve health outcomes for patients worldwide, making it a pivotal platform for scholars and practitioners in the oncology community.

Cancer Biotherapy and Radiopharmaceuticals, an esteemed publication by Mary Ann Liebert, Inc., is a premier journal in the field of oncology that addresses the evolving landscape of cancer treatment through innovative biotherapeutics and radiopharmaceutical interventions. With an ISSN of 1084-9785 and an E-ISSN of 1557-8852, this journal provides a vital platform for researchers, clinicians, and industry experts to share cutting-edge findings and methodologies that shape cancer therapeutic practices. Its impressive impact factor and Scopus ranks highlight its significant contribution to the field, particularly within the categories of Oncology and Radiology, where it consistently secures a position in the upper quartiles. As an open access journal, it enables free dissemination of knowledge, ensuring accessibility for a global audience. By focusing on clinical applications, experimental research, and the latest technological advancements, Cancer Biotherapy and Radiopharmaceuticals serves not only as a repository of knowledge but also as a catalyst for future research and development in cancer therapy, making it an invaluable resource for the academic community and healthcare professionals alike.

CLINICAL & EXPERIMENTAL METASTASIS is a highly regarded academic journal dedicated to the study of cancer metastasis, published by Springer. With an ISSN of 0262-0898 and an E-ISSN of 1573-7276, this journal serves as a pivotal resource for researchers and professionals dedicated to understanding the complexities of metastatic disease. Based in the Netherlands, it boasts an impressive impact factor, solidifying its position in two major quartiles: Q2 in Cancer Research and Q1 in both Medicine (Miscellaneous) and Oncology for 2023. The journal not only ranks among the top tier in Medicine Oncology—84th out of 404—but also excels in Biochemistry, Genetics and Molecular Biology in Cancer Research, ranking 75th out of 230. With coverage spanning from 1983 to 2024, CLINICAL & EXPERIMENTAL METASTASIS presents cutting-edge research, reviews, and clinical studies that drive the field forward. This journal is essential for anyone looking to deepen their understanding of cancer metastasis and its underlying mechanisms.